Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2013

View Archived Issues

Urinary exosomal microRNA downregulated in chronic kidney disease

Novel, non-chemical, approach towards regenerative medical therapy

18F-PS-TumorVue for dual-modality PET/NIRF imaging

Japanese researchers divulge new dimer peptides for diabetes

Emory University and Children's Health Care patent novel fusion proteins

Amarantus BioScience and BD Biosciences to work on test for Alzheimer's disease

Apceth receives approval to conduct stem cell trial in cancer

Bioprojet-Biotech presents novel chemically modified H3 receptor ligands

NICE issues positive appraisal recommendation for Iluvien

Bristol-Myers Squibb and Simcere to develop and commercialize Orencia in China

FDA accepts TherapeuticsMD IND for TX12-004HR

Phase I/II clinical studies of ublituximab presented at the EHA conference

CRT, University of Manchester and AstraZeneca to develop new cancer drugs

Knopp Neurosciences to donate phase III data to ALS database

Chinese team patents novel BMP-2 inhibitors

NGM Biopharmaceuticals and MedImmune partner to develop therapies for diabetes and obesity

Celgene presents analyzed results from the NIMBUS phase III trial

CoMentis and Anvyl sign agreement to form Alpharmagen

European approval for Revlimid in MDS

The U.S. Secretary of the Navy divulges new vaccines for bacterial infections

Prograf approved in Japan in new indication

Maintate approved in Japan for atrial fibrillation

Japanese approval of Precedex in non-intubated patients granted

FDA agrees with proposed trial design for Methylene Blue MMX

Humira prefilled syringe approved in Japan for ulcerative colitis

Chugai obtains new approvals in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...